In Vitro Activity of Tigecycline Among Key Bacterial Pathogens Exhibiting Multidrug Resistance
|Infections, Bacterial||Drug: In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance|
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||In Vitro Activity of Tigecycline Among Key Bacterial Pathogens Exhibiting Multidrug Resistance|
|Study Start Date:||September 2009|
|Estimated Study Completion Date:||July 2012|
|Estimated Primary Completion Date:||June 2012 (Final data collection date for primary outcome measure)|
|Multidrug resistant (MDR)bacterial strains||
Drug: In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance
studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.
Study Phase Definition: Phase of investigation, as defined by the US FDA for trials involving investigational new drugs. Select only one.
N/A: for trials without phases Observational Study Design Case-control: group of individuals with specific characteristics (e.g., conditions or exposures) compared to group(s) with different Time Perspective Cross-sectional: observations or measurements made at a single point in time, usually at subject enrollment Biospecimen Retention - select one Samples Without DNA - samples retained, with no potential for DNA extraction from any retained samples (e.g., fixed tissue, plasma) Biospecimen Description
Sputum, whole blood, urine, tissue Enrollment
Single group study Number of Groups/Cohorts Definition: Number of study groups/cohorts. Enter 1 for a single-group study. Many observational studies have one group/cohort; case control studies typically have two.
One study group, anticipated samples in the rang of 400-500 samples 8. Arms, Groups and Interventions N/L Group/Cohort Label
Please refer to this study by its ClinicalTrials.gov identifier: NCT01132417
|King Faisal Univrsity, Departmentof Microbiology and Immunology,, dammam branh|
|Dammam, Eastern, Saudi Arabia, 31451|
|Principal Investigator:||Asim E Ltayeb Diab, MD, Ph D||Assist. Professor and Consultant Microbiologist|